Shots:

• Sangamo to receive $350 million upfront- including $125M license fee & $225M equity investment in Sangamo’s stock or ~24M shares at $9.21/share and is eligible to receive $2.37B as milestones along with royalties on sales of the therapies
• Biogen to get an exclusive WW right of ST-501 for tauopathies including AD- ST-502 for synucleinopathies including PD and third neuromuscular disease target with exclusive rights for 9 additional targets for 5yrs. The GMP manufacturing activities for the first 3 products will be processed by Sangamo later Biogen will be responsible beyond the first clinical study for each of the first 3 products
• Sangamo will be responsible for early research activities for which cost will be shared b/w the companies while Biogen will take the responsibility and costs for the IND- clinical development- related regulatory interaction and global commercialization of therapies

Click here ­to­ read full press release/ article

| Ref: Biogen | Image: Biogen